Long-Term Deferiprone Resulted in Progressive Improvement in Iron Load in SCD
Researchers sought to determine whether deferiprone would lead to progressive reduction in iron load in patients with SCD or other anemias.
Researchers sought to determine whether deferiprone would lead to progressive reduction in iron load in patients with SCD or other anemias.
Hydroxyurea used by 24.6 percent with sickle cell disease, while l-glutamine, voxelotor, crizanlizumab were used by 2.0, 1.9, and 1.4 percent.
Researchers sought to determine whether vaccination with V114 would lead to similar immunity against the 13 serotypes covered by Prevnar 13 in children with SCD.
Researchers sought to determine the costs associated with SCD in the United States.
Researchers sought to determine the utility of red blood cell transfusion in reducing bone marrow abnormalities in patients with SCD.
Researchers sought to determine whether there was a link between HSCT and normalization of cerebral hemodynamic parameters in children with SCD.
Researchers sought to assess the impact of HSCT on vaso-occlusive events in patients with sickle cell disease.
Researchers sought to determine the risk factors for patients with SCD developing a secondary neoplasm after undergoing HSCT.
Researchers sought to determine whether rivipansel would effectively treat vaso-occlusive crisis in patients with sickle cell disease.
Researchers sought to determine whether care from a multidisciplinary pulmonary clinic would improve health outcomes in patients with SCD.